Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down
by Zacks Equity Research
Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.
Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod
by Zacks Equity Research
Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan
by Zacks Equity Research
Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.
Allergan (AGN) Beats on Q2 Earnings and Sales, Stock Up
by Zacks Equity Research
Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics.
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
Allergan's Depression Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.
Allergan (AGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.
AGN or TLGT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AGN vs. TLGT: Which Stock Is the Better Value Option?
AGN vs. TLGT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AGN vs. TLGT: Which Stock Is the Better Value Option?
Ironwood Begins New Phase III Study to Expand Linzess Label
by Zacks Equity Research
Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.
Novartis Looks to Exit Antibacterial, Antiviral Program
by Zacks Equity Research
Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.
Top Analyst Reports for Union Pacific, 21st Century Fox & BP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), Twenty-First Century Fox (FOXA) and BP plc (BP).
Adamis (ADMP) Surges Following Novartis Deal for Symjepi
by Zacks Equity Research
Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.
The Zacks Analyst Blog Highlights: Bank of America, Wells Fargo, Honeywell, Allergan and Enterprise Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Wells Fargo, Honeywell, Allergan and Enterprise Products
AGN vs. AMPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AGN vs. AMPH: Which Stock Is the Better Value Option?
Has Allergan plc (AGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGN) Outperforming Other Medical Stocks This Year?
Is Allergan (AGN) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Allergan plc (AGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Top Research Reports for Bank of America, Wells Fargo & Honeywell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Wells Fargo (WFC) and Honeywell (HON).
Paratek's Antibiotic Candidate Gets FDA Committee Date
by Zacks Equity Research
Paratek's (PRTK) NDA for its antibiotic candidate, omadacycline, to be reviewed by an FDA advisory committee on Aug 8.
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
by Zacks Equity Research
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
by Zacks Equity Research
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe
by Zacks Equity Research
Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.
Allergan Requests Shareholders to Veto Management Change
by Zacks Equity Research
Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.